PRELIMINARY OBSERVATIONS ON THE VALUE OF DIAZOXIDE ADMINISTERED INTRAVENOUSLY IN MAN
- Antihypertensive agent. // Geriatrics;Apr97, Vol. 52 Issue 4, p36
Presents information about valsatran (Diovan), an angiotensin II receptor blocker which has been approved for the treatment of hypertension. Similarity of valsatran in placebo; Recommended dosage for taking valsatran; Occurrence of antihypertensive effect; Adverse reactions of valsatran.
- Chlorthalidone for hypertension. Elliott, William T. // Neurology Alert;May2013 Pharmacology Watch, p2
The article discusses a study published in a 2013 issue of "Annals of Internal Medicine" which noted that chlorthalidone may cause more electrolyte abnormalities than hydrochlorothiazide (HCTZ).
- Randomised controlled trial of treatment for mild hypertension: design and pilot trial. // British Medical Journal;6/4/77, Vol. 1 Issue 6074, p1437
Presents a design and pilot trial for treating mild and moderate hypertension. Efficacy of drug treatment for hypertension; Determination on the effect of antihypertensive treatment in adults of either sex; Benefits of antihypertensive treatment.
- Increasing the Dietary Potassium Intake Reduces the Need for Antihypertensive Medication. // Annals of Internal Medicine;11/15/91, Vol. 115 Issue 10, p753
Presents a study which determined whether an increase in dietary potassium intake from natural foods reduces the need for antihypertensive medication in patients with essential hypertension. Methods; Drug therapy protocols; Results; Discussion; Conclusion.
- Millions of mild hypertensives. // British Medical Journal;10/18/1980, Vol. 281 Issue 6247, p1024
Examines the treatment for mild hypertensive in Great Britain. Management of blood pressure levels; Cautions on the fatal and non-fatal complications; Efficacy of drugs as treatment.
- A NEW BASE LINE FOR THE EVALUATION OF ANTIHYPERTENSIVES. Grenfell, Raymond F.; Briggs, Arthur H.; Holland, William C. // Angiology;Nov1962, Vol. 13 Issue 11, p495
In the parenteral placebo group, there was a significant decrease in the systolic blood pressure for 63 weeks and in the diastolic blood pressure for 147 weeks when compared to the blood pressure in week 0 of treatment. There was a significant decrease in the systolic blood pressure in these...
- Beyond Hypertension: Metabolic Effects of Telmisartan. Kuritzky, Louis // Neurology Alert;Jul2013 Clincal Briefs, p1
The article discusses research on the effect of Telmisartan in patients with metabolic syndrome, referencing a study by H. Takagi and colleagues published in an issue of the "Journal of the American Society of Hypertension."
- Association between prescription burden and medication adherence in patients initiating antihypertensive and lipid-lowering therapy. Benner, Joshua S.; Chapman, Richard H.; Petrilla, Allison A.; Tang, Simon S. K.; Rosenberg, Noah; Schwartz, J. Sanford // American Journal of Health-System Pharmacy;8/15/2009, Vol. 66 Issue 16, p1471
Purpose. The association between prescription burden and medication adherence in patients initiating antihypertensive and lipid-lowering therapy was studied. Methods. Patients enrolled in managed care organizations who initiated antihypertensive therapy coincident with lipid-lowering therapy (no...
- The value of 24-h blood pressure monitoring to assess the efficacy of antihypertensive drug treatment. O'Brien, Eoin // Hot Topics in Hypertension;2011, Vol. 4 Issue 12, p7
Ambulatory blood pressure monitoring (ABPM) in pharmacological trials has evolved over the years. It is now evident that its advantages greatly outweigh the limitations arising from BP measurements taken in the clinic. While early studies of antihypertensive drugs were restricted by the need for...